Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899402 · ClinicalTrials.gov registry record · Phase 2
Triple Therapy in T1DM
A Phase 2 study of Type 1 Diabetes Mellitus, sponsored by State University of New York at Buffalo.
- Active
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT03899402: Active Phase 2 study of Type 1 Diabetes Mellitus, sponsored by State University of New York at Buffalo.
NCT03899402 is a Phase 2 study of Type 1 Diabetes Mellitus that is active but no longer recruiting, run by State University of New York at Buffalo. The registered enrollment target is 78 participants, below the 171-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03899402, a Phase 2 study of Type 1 Diabetes Mellitus, is active but no longer recruiting, sponsored by State University of New York at Buffalo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Primary Outcome
Change in HbA1c at 6 months following dapagliflozin or placebo therapy in addition to combined semaglutide and insulin treatment.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Insulin
- DRUG Dapagliflozin
- DRUG Placebo to Dapagliflozin
Study Locations (1)
New York
- Diabetes and Endocrinology Research Center of WNY - Williamsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What the registry record for NCT03899402 still lists
NCT03899402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 171-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.
NCT03899402 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03899402 about?
NCT03899402 is a clinical study titled "Triple Therapy in T1DM". To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
What is the current status of trial NCT03899402?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2019-05-01. Estimated completion is 2026-03-31.
What conditions does trial NCT03899402 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT03899402?
The interventions under investigation include: Semaglutide (DRUG), Insulin (DRUG), Dapagliflozin (DRUG), Placebo to Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT03899402?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899402 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03899402's enrollment target sits among peer trials
78 38th of 112 higher than 75 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
-
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
RECRUITING · Phase 2
-
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Probiotics in Newly Diagnosed T1D
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI